Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients
Abstract Molecular Tumour Boards (MTBs) play a crucial role in interpreting genomic results and providing treatment recommendations. We investigated the real-world impact of MTBs on clinical decision-making by surveying health care professionals (HCPs) across the UK; 44 participants from 11 MTBs too...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00863-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063830464331776 |
|---|---|
| author | Julio Herrero Colomina Eleanor Johnston Kate Duffus Zoulikha M. Zaïr Fiona Thistlethwaite Matthew Krebs Louise Carter Donna Graham Natalie Cook |
| author_facet | Julio Herrero Colomina Eleanor Johnston Kate Duffus Zoulikha M. Zaïr Fiona Thistlethwaite Matthew Krebs Louise Carter Donna Graham Natalie Cook |
| author_sort | Julio Herrero Colomina |
| collection | DOAJ |
| description | Abstract Molecular Tumour Boards (MTBs) play a crucial role in interpreting genomic results and providing treatment recommendations. We investigated the real-world impact of MTBs on clinical decision-making by surveying health care professionals (HCPs) across the UK; 44 participants from 11 MTBs took part in the study. 97.7% of respondents felt that MTBs increased awareness of available clinical trials matched to genomic alterations, 84% reported more confidence in interpreting genomic data, and 95.4% valued MTBs as educational. Hurdles to the discussion at MTBs included frequency and capacity of MTBs (ctDNA), sample collection and laboratory turnaround time (Tissue samples). One-third of respondents encountered challenges attending MTBs regularly due to workload. The survey highlighted areas for optimisation, such as meeting efficiency, rapid molecular analysis turnaround time, reliable trial matching tools, and ensuring MTBs are included in HCP's job plans. |
| format | Article |
| id | doaj-art-e7e4ce86a4ac4bd9bd50aeb596514dd7 |
| institution | DOAJ |
| issn | 2397-768X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj-art-e7e4ce86a4ac4bd9bd50aeb596514dd72025-08-20T02:49:29ZengNature Portfolionpj Precision Oncology2397-768X2025-03-01911810.1038/s41698-025-00863-3Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patientsJulio Herrero Colomina0Eleanor Johnston1Kate Duffus2Zoulikha M. Zaïr3Fiona Thistlethwaite4Matthew Krebs5Louise Carter6Donna Graham7Natalie Cook8The Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustThe Christie NHS Foundation TrustAbstract Molecular Tumour Boards (MTBs) play a crucial role in interpreting genomic results and providing treatment recommendations. We investigated the real-world impact of MTBs on clinical decision-making by surveying health care professionals (HCPs) across the UK; 44 participants from 11 MTBs took part in the study. 97.7% of respondents felt that MTBs increased awareness of available clinical trials matched to genomic alterations, 84% reported more confidence in interpreting genomic data, and 95.4% valued MTBs as educational. Hurdles to the discussion at MTBs included frequency and capacity of MTBs (ctDNA), sample collection and laboratory turnaround time (Tissue samples). One-third of respondents encountered challenges attending MTBs regularly due to workload. The survey highlighted areas for optimisation, such as meeting efficiency, rapid molecular analysis turnaround time, reliable trial matching tools, and ensuring MTBs are included in HCP's job plans.https://doi.org/10.1038/s41698-025-00863-3 |
| spellingShingle | Julio Herrero Colomina Eleanor Johnston Kate Duffus Zoulikha M. Zaïr Fiona Thistlethwaite Matthew Krebs Louise Carter Donna Graham Natalie Cook Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients npj Precision Oncology |
| title | Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients |
| title_full | Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients |
| title_fullStr | Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients |
| title_full_unstemmed | Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients |
| title_short | Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients |
| title_sort | real world experience of molecular tumour boards for clinical decision making for cancer patients |
| url | https://doi.org/10.1038/s41698-025-00863-3 |
| work_keys_str_mv | AT julioherrerocolomina realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT eleanorjohnston realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT kateduffus realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT zoulikhamzair realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT fionathistlethwaite realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT matthewkrebs realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT louisecarter realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT donnagraham realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients AT nataliecook realworldexperienceofmoleculartumourboardsforclinicaldecisionmakingforcancerpatients |